Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M. Dunbier AK, et al. Among authors: ellis mj. J Clin Oncol. 2010 Mar 1;28(7):1161-7. doi: 10.1200/JCO.2009.23.9616. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124184 Free PMC article.
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Ellis MJ, et al. J Clin Oncol. 2001 Sep 15;19(18):3808-16. doi: 10.1200/JCO.2001.19.18.3808. J Clin Oncol. 2001. PMID: 11559718 Clinical Trial.
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Osborne CK, et al. J Clin Oncol. 2002 Aug 15;20(16):3386-95. doi: 10.1200/JCO.2002.10.058. J Clin Oncol. 2002. PMID: 12177098 Clinical Trial.
Successful targeting of ErbB2 receptors-is PTEN the key?
Crowder RJ, Lombardi DP, Ellis MJ. Crowder RJ, et al. Among authors: ellis mj. Cancer Cell. 2004 Aug;6(2):103-4. doi: 10.1016/j.ccr.2004.08.001. Cancer Cell. 2004. PMID: 15324690 Free article.
Functional analysis of the breast cancer genome.
Ellis MJ. Ellis MJ. J Clin Oncol. 2006 Apr 10;24(11):1649-50. doi: 10.1200/JCO.2005.05.3520. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505408 No abstract available.
The molecular portraits of breast tumors are conserved across microarray platforms.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. Hu Z, et al. Among authors: ellis mj. BMC Genomics. 2006 Apr 27;7:96. doi: 10.1186/1471-2164-7-96. BMC Genomics. 2006. PMID: 16643655 Free PMC article.
529 results